Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Insulet Corporation
DexCom, Inc.
Quanterix Corporation Common Stock
SI-BONE, Inc. Common Stock
Penumbra, Inc.
Zimmer Biomet Holdings, Inc.
Lantheus Holdings, Inc
HealthEquity, Inc
The chart shows the growth of an initial investment of $10,000 in Haemonetics Corporation, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Haemonetics Corporation (HAE) has returned -29.20% so far this year and -4.47% over the past 12 months. Looking at the last ten years, HAE has achieved an annualized return of 4.86%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
The table below presents the monthly returns of Haemonetics Corporation (HAE) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.96% | -5.11% | -10.71% | 0.98% | ||||||||
| 2025 | -11.89% | -3.61% | -2.98% | -0.69% | 6.78% | 10.58% | 0.24% | -26.35% | -10.57% | 2.82% | 63.03% | -0.93% |
| 2024 | -10.07% | -4.76% | 17.16% | 7.27% | -8.71% | -2.03% | 8.60% | -15.96% | 7.17% | -11.39% | 22.15% | -11.15% |
| 2023 | 6.03% | -8.56% | 6.62% | 2.09% | 0.70% | 0.21% | 8.95% | -2.52% | -0.93% | -4.85% | -4.78% | 5.65% |
| 2022 | -9.32% | 17.78% | 9.19% | -19.89% | 24.50% | 2.74% | 5.75% | 9.20% | -0.66% | 13.31% | -0.20% | -8.25% |
| 2021 | -4.54% | 10.96% | -13.05% | -39.71% | -16.14% | 19.13% | -8.72% | 3.87% | 11.69% | -2.92% | -25.53% | 1.07% |
| 2020 | -7.49% | 0.42% | -8.36% | 18.82% | -2.39% | -18.34% | -1.59% | 1.79% | -2.76% | 15.22% | 10.94% | 4.00% |
| 2019 | -11.79% | -0.14% | -1.04% | 9.59% | 23.68% | 0.32% | 9.47% | -4.42% | -4.92% | -3.95% | -5.05% | |
| 2018 | 4.56% | 10.14% | 3.23% | 6.66% | 16.00% | -1.35% | 9.43% | 14.73% | 2.47% | -9.38% | 2.45% | -7.97% |
| 2017 | -0.97% | -7.05% | 7.50% | 3.20% | -2.51% | -3.28% | 3.32% | 4.32% | 4.16% | 5.69% | 20.95% | 0.89% |
| 2016 | -6.62% | -6.67% | 3.35% | 4.37% | 21.84% | -2.61% | -7.66% | 18.55% | 1.85% |
The charts below present risk-adjusted performance metrics for Haemonetics Corporation (HAE) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of HAE compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
The current Haemonetics Corporation volatility is 1.48%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.45B | 2.20B | 1.93B | 1.86B | 1.82B | 1.27B | 1.27B | 1.24B | 1.24B | 1.32B | 1.49B | 1.51B | 1.46B | 911.14M | 833.26M |
| Equity Attributable To Parent (USD) | 820.84M | 959.96M | 818.00M | 749.42M | 731.67M | 587.11M | 667.87M | 752.43M | 739.61M | 721.57M | 826.12M | 837.89M | 769.18M | 732.63M | 686.14M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 820.84M | 959.96M | 818.00M | 749.42M | 731.67M | 587.11M | 667.87M | 752.43M | 739.61M | 721.57M | 826.12M | 837.89M | 769.18M | 732.63M | 686.14M |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | 3.55M | 39.72M | 19.08M | 32.50M | 43.99M | - |
| Long-term Debt (USD) | 1.25B | - | - | - | - | - | - | - | 315.81M | 408.47M | 430.48M | 440.29M | 480.09M | 3.77M | - |
| Noncurrent Liabilities (USD) | 1.05B | 935.25M | 865.01M | 668.04M | 834.76M | 405.18M | 371.14M | 100.21M | 287.92M | 412.01M | 470.20M | 459.36M | 512.59M | 47.76M | 38.46M |
| Other Current Liabilities (USD) | 451.69M | 146.32M | 123.41M | 335.36M | 155.60M | 174.62M | 119.20M | 259.92M | 124.67M | 110.08M | 89.55M | 108.45M | 84.55M | 65.87M | 53.31M |
| Wages (USD) | 59.42M | 80.71M | 64.48M | 48.54M | 47.60M | 49.47M | 53.20M | 69.52M | 43.53M | 35.80M | 51.12M | 54.91M | 45.70M | 29.45M | 27.04M |
| Accounts Payable (USD) | 67.00M | 73.36M | 63.93M | 58.37M | 50.29M | 50.73M | 63.36M | 55.27M | 42.97M | 39.67M | 48.43M | 53.56M | 49.89M | 35.43M | 28.32M |
| Current Liabilities (USD) | 578.11M | 300.38M | 251.82M | 442.27M | 253.50M | 274.82M | 235.76M | 384.70M | 211.18M | 185.55M | 189.09M | 216.93M | 180.14M | 130.74M | 108.67M |
| Liabilities (USD) | 1.63B | 1.24B | 1.12B | 1.11B | 1.09B | 680.00M | 606.90M | 484.91M | 499.10M | 597.56M | 659.30M | 676.29M | 692.74M | 178.50M | 147.13M |
| Other Non-current Assets (USD) | 776.18M | 709.21M | 578.45M | 534.96M | 543.34M | 276.97M | 226.97M | 227.42M | 227.28M | 288.95M | 593.19M | 619.77M | 607.95M | 222.35M | 228.91M |
| Intangible Assets (USD) | 455.74M | 406.12M | 275.77M | 310.26M | 365.48M | 133.11M | 127.69M | 156.59M | 177.54M | 204.46M | - | - | - | - | - |
| Fixed Assets (USD) | 284.05M | 311.36M | 310.89M | 258.48M | 217.56M | 253.40M | 343.98M | 332.16M | 323.86M | 337.63M | 321.95M | 271.44M | 256.95M | 161.66M | 155.53M |
| Noncurrent Assets (USD) | 1.52B | 1.43B | 1.17B | 1.10B | 1.13B | 663.47M | 698.65M | 716.16M | 728.68M | 831.04M | 915.14M | 891.20M | 864.91M | 384.01M | 384.43M |
| Other Current Assets (USD) | 569.83M | 451.70M | 510.34M | 463.00M | 370.93M | 333.36M | 381.78M | 360.38M | 333.10M | 301.06M | 359.20M | 425.32M | 413.23M | 409.97M | 364.44M |
| Inventory (USD) | 365.14M | 317.20M | 259.38M | 293.03M | 322.61M | 270.28M | 194.34M | 160.80M | 176.93M | 187.03M | 211.08M | 197.66M | 183.78M | 117.16M | 84.39M |
| Current Assets (USD) | 934.98M | 768.90M | 769.72M | 756.03M | 693.55M | 603.64M | 576.12M | 521.18M | 510.03M | 488.09M | 570.28M | 622.98M | 597.01M | 527.13M | 448.83M |
| Assets (USD) | 2.45B | 2.20B | 1.93B | 1.86B | 1.82B | 1.27B | 1.27B | 1.24B | 1.24B | 1.32B | 1.49B | 1.51B | 1.46B | 911.14M | 833.26M |
Haemonetics Corporation announced the acquisition of Ireland-based Vivasure Medical Limited for €100 million upfront plus up to €85 million in milestone-based payments. The deal adds Vivasure's PerQseal Elite system, a bioabsorbable patch for large-bore vascular access closure, to Haemonetics' interventional portfolio. The technology has received CE Mark approval in Europe and submitted FDA Premarket Approval in the U.S., with strong clinical data showing no major complications.
The Patient Blood Management market is projected to grow from $13.9 billion in 2025 to $23 billion by 2033, driven by AI-enhanced analytics, autologous transfusion technologies, and advancements in blood conservation techniques.
Haemonetics reported Q1 FY2026 financial results with revenue of $321.4 million, missing analyst expectations. Despite revenue decline, the company showed strong organic growth in Plasma and Hospital segments and improved margins.
The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.
The global apheresis equipment market is expected to grow from $4.17 billion in 2023 to $13.17 billion by 2033, at a CAGR of 12.2%. Key drivers include the increasing prevalence of chronic diseases, technological advancements, and growing demand for blood components.
The global blood recovery machine market is expected to grow at a CAGR of 5.9% from 2024 to 2033, driven by advancements in medical technologies, increased awareness of autologous blood transfusion benefits, and rising demand for surgical procedures.
Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.
Thermo Fisher Scientific reported better-than-expected Q2 2024 results, with adjusted EPS of $5.37 and revenue of $10.54 billion. The company saw margin expansion but a decline in both reported and organic revenues, particularly in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.
Elanco Animal Health has divested its aqua business to Merck Animal Health for $1.3 billion, enabling the company to focus on pet health and livestock sustainability while reducing its debt burden.
Globus Medical is gaining market share in the musculoskeletal solutions space, driven by strong performance of its products. However, the company is facing challenges from global economic factors, including rising costs and inflation.